QuantideX® qPCR BCR-ABL minor Kit (RUO)

BCR-ABL blood cancer cellsThe QuantideX® qPCR BCR-ABL minor Kit (RUO) is a clinical research tool enabling ultra-sensitive and precise detection of BCR-ABL1 minor fusion transcripts (e1a2) from whole blood specimens. Building on the simple workflow and best-in-class sensitivity established with the FDA-cleared QuantideX® qPCR BCR-ABL IS Kit, the minor Kit allows labs and clinical researchers to examine the biology of disease for this very rare but distinct leukemic variant with unprecedented ease.

Features & Benefits

The QuantideX qPCR BCR-ABL minor Kit (RUO) delivers high performance through unmatched sensitivity and optimized laboratory efficiency.

Reduced Complexity
Ease-of-data analysis and reporting:

  • Leverages the QuantideX® qPCR BCR-ABL IS Kit workflow concept for streamlined implementation
  • Included software provides automated calculation of BCR-ABL1/ABL1 % ratio and eliminates the need for manual calculation

Optimized Workflow
Valuable operator hands-on time has been significantly reduced through:

  • Multiplexed design amplifies and detects both fusion and control gene in the same reaction
  • All-inclusive reagents sourced and quality controlled together from a single vendor
  • Pre-mixed reagents allow fewer pipetting steps in mastermix preparation

Quality Performance
Detecting BCR-ABL1 minor transcripts robustly and reliably with a highly sensitive assay:

  • Ultra-sensitive Limit of Detection (LOD): Log reduction of 4.61 (0.0025% ratio)
  • Increased analytical sensitivity without compromising analytical specificity: incorporates Limit of Blank (LOB) to prevent miscalling of non-leukemic low positives
  • Armored RNA®-based standards provide true RNA quantification

Analytical Characteristics

  • Reproducible: Proven sensitivity based on rigorous testing criterion (Table 1)
  • Precise: Minimal variability across entire dynamic range of BCR-ABL1/ABL1 % ratios (Table 2)
  • Streamlined: Multiplexed design yields workflow and cost efficiencies (Figure 1)

Proven Sensitivity Based on Rigorous Testing Criterion
Table 1: LOD as determined by CLSI EP17-A2 guidelines by testing human RNA and cell line dilutions spanning lots, batch runs, days, operators and instruments.

Minimal Variability across Entire Dynamic Range

Table 2: Assay precision determined by testing 4 different log reduction (LR) levels in human RNA, using 2 operators and 8 runs for a total of 192 data points.

 

Multiplexed Design Yields Workflow and Cost Efficiency
  

 

 

 


Figure 1: 
Comparison of a plate layout for 8 sample run on Asuragen plate (left) and an alternate non-multiplex assay (right): 19 reactions for Asuragen setup vs. 52 reactions on a non-multiplex assay setup

Ordering

Product Name Number of Reactions Catalog Number
QuantideX® qPCR BCR-ABL minor Kit (RUO) 60 49637

T 512.681.5200 or 877.777.1874
F 512.681.5202
E orders@asuragen.com

QuantideX® qPCR BCR-ABL minor Kit

The BCR-ABL1 minor breakpoint (e1a2) constitutes a rare but distinct leukemic variant and accurate detection and quantitation of these fusion transcripts are paramount to improving outcomes for all chronic myeloid leukemia (CML) patients. The QuantideX® qPCR BCR-ABL minor Kit, an in vitro diagnostic (IVD) assay, enables ultra-sensitive detection of BCR-ABL1 minor fusion transcripts from whole blood specimens.

 

Features & Benefits

The QuantideX qPCR BCR-ABL minor Kit marries improved efficiency with unprecedented sensitivity, empowering labs to assess the deepest molecular responses in patients harboring the minor breakpoint with the ease-of-use they’ve come to expect from Asuragen.

Reduced Complexity
Ease-of-data analysis and reporting:

  • Shares a common workflow with the QuantideX® qPCR BCR-ABL IS Kit to reduce training burden and streamline test implementation
  • Included software provides automated calculation of BCR-ABL1/ABL1 % ratio and the ability to report BCR-ABL Major on both the International Scale (IS) and copy number*

Optimized Workflow
Valuable operator hands-on time has been significantly reduced through:

  • Multiplexed design amplifies and detects both fusion and control gene in the same reaction
  • All necessary RT and qPCR reagents sourced and quality controlled together from a single vendor
  • Pre-mixed reagents allow fewer pipetting steps in mastermix preparation

Quality Performance
Detecting BCR-ABL1 minor transcripts robustly and reliably with a highly sensitive assay:

  • Ultra-sensitive Limit of Detection (LOD): Log reduction of 4.61 (0.0025% ratio)
  • Increased analytical sensitivity without compromising analytical specificity: incorporates Limit of Blank (LOB) to prevent miscalling of non-leukemic low positives
  • Armored RNA®-based standards provide true RNA quantification

Download Brochure

 

 

Analytical Characteristics

  • Reproducible: Proven sensitivity based on rigorous testing criterion (Table 1)
  • Precise: Minimal variability across entire dynamic range of BCR-ABL1/ABL1 % ratios (Table 2)
  • Streamlined: Multiplexed design yields workflow and cost efficiencies (Figure 1)

Proven Sensitivity Based on Rigorous Testing Criterion
Table 1: LOD as determined by CLSI EP17-A2 guidelines by testing human RNA and cell line dilutions spanning lots, batch runs, days, operators and instruments.

Minimal Variability across Entire Dynamic Range

Table 2: Assay precision determined by testing 4 different log reduction (LR) levels in human RNA, using 2 operators and 8 runs for a total of 192 data points.

 

Multiplexed Design Yields Workflow and Cost Efficiency
  

 

 

 


Figure 1: 
Comparison of a plate layout for 8 sample run on Asuragen plate (left) and an alternate non-multiplex assay (right): 19 reactions for Asuragen setup vs. 52 reactions on a non-multiplex assay setup

Ordering

Product Name Number of Reactions Catalog Number
QuantideX® qPCR BCR-ABL minor Kit 60 49640

T +1 512.681.5200 or +1 877.777.1874
F +1 512.681.5202
E orders@asuragen.com

Back To
Top